In 33 years of continuous development, Livzon Pharmaceutical Group Inc. has won many national industry honors. Its product Lizhu Dele was widely recognized in 1989. ShenQi FuZheng Injection was approved for production in 1999, and has successively won the First Prize of the Guangdong Scientific & Technological Progress Award and the second prize of National Scientific & Technological Progress Award. Anti-Viral Granules won the First Prize of the Scientific & Technological Award from the China Association of Traditional Chinese Medicine in 2001. LiShenBao (Urofollitropin for Injection) has won the Second Prize of Guangdong Scientific & Technological Progress Award. The primary new drug Ilaprazole was successively awarded the First Prize of Guangdong Scientific & Technological Progress Award and the Second Prize of National Scientific & Technological Progress Award.

The 3^rd Chinese Pharmaceutical R&D and Innovation Conference was held on June 29 and 30, 2018. As evaluated by the organizing committee and China Pharmacy Magazine for the Drug R&D strength, Livzon Pharmaceutical Group was rated Top 10 in Chinese Bio-Pharmaceutical R&D Strength, Top 100 in Chinese Chemical R&D Strength, and Top 20 in Chinese Comprehensive Drug R&D Strength. Livzon Pharmaceutical Group Inc. previously won these honors in 2017.